Barda,NIH and Regeneron are recruiting/funding a trial with several unknown MABs. So if funding comes from something like that then fine have at it. Jay also mentioned long Covid in the last two CCs so take it for what it’s worth.


https://investor.regeneron.com/news-releases/...pment-next